Symbols / ARAY

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• Insider Purchase: Director at $ARAY Buys 54,875 Shares - Quiver Quantitative Mon, 23 Feb 2026 21
• Accuray (NASDAQ: ARAY) targets $25M profit lift, plans $11M in restructuring - Stock Titan Mon, 15 Dec 2025 08
• Accuray Warned by Nasdaq Over Sub‑$1 Share Price, Faces Rising Delisting and Liquidity Risks - The Globe and Mail hu, 19 Feb 2026 08
• Insider Makes Bold Move With Fresh Buy Into Accuray Stock - TipRanks Sat, 21 Feb 2026 11
• The past five years for Accuray (NASDAQ:ARAY) investors has not been profitable - Yahoo Finance Sun, 11 Jan 2026 08
• Accuray Reports Fiscal 2026 First Quarter Financial Results - PR Newswire Wed, 05 Nov 2025 08
• Would You Still Hold Accuray Stock If It Fell Another 30%? - Trefis Sun, 21 Dec 2025 08
• Groundhog Day Once Again, As Accuray Misses And Lowers - Seeking Alpha Fri, 06 Feb 2026 08
• The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33% - simplywall.st Fri, 06 Feb 2026 08
• BTIG Maintains Accuray (ARAY) Buy Recommendation - Nasdaq hu, 06 Nov 2025 08
• $ARAY stock is down 20% today. Here's what we see in our data. - Quiver Quantitative hu, 05 Feb 2026 08
• Accuray’s Latest Transformation Attempt Could Be Too Little Too Late (NASDAQ:ARAY) - Seeking Alpha hu, 06 Nov 2025 08
• $92.5–94M Q1 revenue — Accuray appoints Steve La Neve CEO to lead transformation, board adds Steven F. Mayer - Stock Titan Mon, 20 Oct 2025 07
• Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules - PR Newswire Fri, 31 Oct 2025 07
• Accuray Releases Updated Investor Presentation Under Regulation FD - The Globe and Mail Wed, 18 Feb 2026 08

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 42026-02-23 View
• 42026-02-20 View
• 8-K2026-02-17 View
• 10-Q2026-02-17 View
• 8-K2026-02-09 View
• 8-K2026-02-06 View
• 8-K2026-02-04 View
• 8-K2026-01-20 View
• 42026-01-09 View
• 8-K2025-12-31 View
• 8-K2025-12-16 View
• 42025-12-02 View
• 42025-12-02 View
• 42025-12-02 View
• 42025-12-02 View